Equity Overview
Price & Market Data
Price: $0.58
Daily Change: +$0.58 / 100.0%
Daily Range: $0.513 - $0.62
Market Cap: $17,014,594
Daily Volume: 2,074,151
Performance Metrics
1 Week: 59.31%
1 Month: 51.16%
3 Months: 18.40%
6 Months: -8.40%
1 Year: -65.33%
YTD: -10.97%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country:
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.